PHARM Pharming Group NV

Pharming Group to report first quarter 2024 financial results on May 8

Pharming Group to report first quarter 2024 financial results on May 8

Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period ended March 31, on Wednesday, May 8, 2024.

Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on May 8, 2024.

To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.

Conference call registration:

Please note, the Company will only take questions from dial-in attendees.

To watch the live webcast, please register in advance using the link below.

Webcast registration:

About Pharming Group N.V.

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit and find us on .

For further public information, contact:

Pharming Group, Leiden, The Netherlands

Michael Levitan, VP Investor Relations & Corporate Communications

T: +1 (908) 705 1696

E:

FTI Consulting, London, UK

Victoria Foster Mitchell/Alex Shaw/Amy Byrne

T: 0

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands

Leon Melens

T: 27

E:

 



EN
24/04/2024

Underlying

PHARMPharming Group NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharming Group NV

 PRESS RELEASE
Free
PHARM Pharming Group ...

Pharming Group to participate in November investor conference

Pharming Group to participate in November investor conference Leiden, the Netherlands, November 5, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of November: Jefferies London Healthcare Conference 2024, London, U.K., November 19-21Sijmen de Vries, Chief Executive Officer, will present on Wednesday, November 20 at 08:00 GMT/09:00 CET. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharmin...

November 5, 2024 1 EN
 PRESS RELEASE
Free
PHARM Pharming Group ...

Pharming Group to report third quarter 2024 financial results on Octob...

Pharming Group to report third quarter 2024 financial results on October 24 Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2024 financial results, for the period ended September 30, on Thursday, October 24, 2024.Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on October 24, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique ...

October 10, 2024 1 EN
 PRESS RELEASE
Free
PHARM Pharming Group ...

Pharming Group announces start of Phase II clinical trial of leniolisi...

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to include ALPS-FAS, CTLA4 haploinsufficiency, NFKB1 haploinsufficiency and PTEN deficiency, with prevalence approximately five times that of APDS  Clinical trial being conducted at the National Institutes of Health (NIH) Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming” or “the Comp...

October 10, 2024 1 EN
 PRESS RELEASE
Free
PHARM Pharming Group ...

Pharming announces marketing authorization in the U.K. for Joenja® (le...

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib) For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, September 26, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Joenja® (leniolisib) for the treatment of activated phosphoinosi...

September 26, 2024 1 EN
 PRESS RELEASE
Free
PHARM Pharming Group ...

Pharming Group to participate in September investor conferences

Pharming Group to participate in September investor conferences Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September: 2024 Wells Fargo Healthcare Conference, Boston, September 4-6Sijmen de Vries, Chief Executive Officer, will participate in a fireside chat question and answer session on Friday, September 6 at 08:45 AM ET/14:45 CET. A live webcast and replay of the presentation will be available i...

September 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch